Full Press Release Details
PolyPid Announces Completion of Enrollment in
Phase 3 SHIELD I Trial of D-PLEX100 for Prevention of
Surgical Site Infections in Abdominal
Unblinded Interim Efficacy Analysis, Data Safety Monitoring Board Recently Recommended Concluding Study at 950 Patients, the Minimum
Number of Patients Targeted
Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1 2023
PETACH TIKVA, Israel, May 31, 2022 -- PolyPid
Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma
company aiming to improve surgical outcomes, announced today the completion of enrollment in the SHIELD I Phase 3 study of D-PLEX100
for the prevention of surgical site infections (SSIs) in abdominal surgery. Following a review of unblinded efficacy data
from the first 750 enrolled patients in the trial, the independent Data Safety Monitoring
Board (DSMB) recently recommended concluding the study upon enrollment of 950 patients, which is the minimum number of targeted patients
in the trial protocol.
"The conclusion of enrollment in the pivotal SHIELD I trial,
the largest colorectal surgery clinical study conducted in more than a decade, represents an important milestone for our D-PLEX100
development program and our company as a whole," stated Amir Weisberg, PolyPid's Chief Executive Officer. "We
look forward to the availability of top-line results from SHIELD I by the end of the third quarter of 2022. Subsequent to these expected
data, we intend to pursue a pre-NDA meeting with the FDA to discuss a rolling NDA submission, consistent with the Breakthrough Therapy
Designation previously granted, with potential NDA and MAA submissions planned for the first half of 2023. We are also focused on further
advancing commercial pre-launch activities, while expediting partnership discussions in and outside of the United States."
I (Surgical site Hospital
acquired Infection prEvention
with Local D-PLEX) is
a prospective, multinational, randomized, double blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX100
administered concomitantly with standard of care (SoC), which includes prophylactic systemic antibiotics,
compared to a SoC alone arm, in prevention of post abdominal surgery incisional infection. The primary endpoint of the trial is the combination
of incisional SSIs and mortality rate as measured by the proportion of subjects with either an SSIs event, as determined by a blinded
and independent adjudication committee, or mortality for any reason within 30 days post-surgery. The trial has enrolled patients in more
than 60 centers in the United States, Europe and Israel.
D-PLEX100, PolyPid's
lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to
prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation
matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous
release of the broad-spectrum antibiotic doxycycline, resulting in high local concentration of the drug for a period of 30 days for the
prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100
received Breakthrough Therapy Designation from the U.S. FDA for the prevention of SSIs in patients undergoing elective colorectal surgery.
D-PLEX100 also received three Qualified Infectious Disease Product (QIDP) designations, and three Fast Track designations for
the prevention of SSIs in patients undergoing elective colorectal surgery, post-abdominal surgery incisional infection and for the prevention
of sternal wound infection post-cardiac surgery.
PolyPid Ltd. (Nasdaq: PYPD)
is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release
therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients,
enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product
candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue
abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy
of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com
Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act
and other securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions or variations of such
words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses
the Company's expectation to report top-line results of the SHIELD I Phase 3
study by the end of the third quarter of 2022, potential NDA submission to FDA and a European Union MAA filing targeted in the first half
of 2023, the Company's intention to pursue a pre-NDA meeting with the FDA to discuss a rolling NDA submission and expedition of partnership
discussions in and outside of the United States. Forward-looking statements are not historical facts, and are based upon management's
current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections
will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking
statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed
in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is
made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"),
including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed on February 28, 2022. Forward-looking
statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to
reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking
information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements,
no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking
References and links to websites have been
provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is
not responsible for the contents of third-party websites.
Dikla Czaczkes Akselbrad